Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma including after treatment with sorafenib: Real-world evidence and
FGFR
hepatic reserve function
hepatocellular carcinoma
lenvatinib
sorafenib
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
30 Jun 2020
30 Jun 2020
Historique:
received:
02
04
2020
accepted:
01
06
2020
entrez:
14
7
2020
pubmed:
14
7
2020
medline:
14
7
2020
Statut:
epublish
Résumé
The efficacy and safety of lenvatinib (LEN) as a second/third-line treatment for unresectable hepatocellular carcinoma (HCC) after sorafenib (SOR) therapy remains unknown. We evaluated the outcomes of second/third-line LEN treatment, investigated the sensitivity of a SOR-resistant HCC cell line (PLC/PRF5-R2) to LEN, and assessed their signal transduction pathways by protein array analysis. We retrospectively enrolled 57 patients with unresectable HCC. Fifty-three radiologically evaluated patients comprised 34 molecular-targeted agent (MTA)-naive (first-line), nine intolerant to SOR (second-line), and 10 resistant to regorafenib (third-line). The objective response rates (ORRs) were 61.8% in first-line, 33.3% in second-line, and 20.0% in third-line groups. The overall survival (OS) in the first-line was significantly longer than that in the third-line group (
Identifiants
pubmed: 32655838
doi: 10.18632/oncotarget.27640
pii: 27640
pmc: PMC7335665
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2531-2542Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST The authors declare they have no conflicts of interest.
Références
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
Semin Liver Dis. 1999;19(3):329-38
pubmed: 10518312
Invest New Drugs. 2018 Apr;36(2):332-339
pubmed: 28891038
N Engl J Med. 2018 Jul 05;379(1):54-63
pubmed: 29972759
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
Mol Cancer Res. 2020 Apr;18(4):549-559
pubmed: 31941753
Hepatol Res. 2018 Sep;48(10):814-820
pubmed: 29682855
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Am J Clin Nutr. 2005 Sep;82(3):531-7
pubmed: 16155264
Hepatol Int. 2019 Mar;13(2):199-204
pubmed: 30671808
Hepatol Res. 2019 Sep;49(9):1054-1065
pubmed: 31033165
Am J Clin Nutr. 1996 Oct;64(4):552-8
pubmed: 8839499
Vasc Cell. 2014 Sep 06;6:18
pubmed: 25197551
Cancers (Basel). 2019 Jul 07;11(7):
pubmed: 31284682
Oncology. 2018;95(2):91-99
pubmed: 29723866
J Gastroenterol. 2019 Jun;54(6):558-570
pubmed: 30788569
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Lancet Oncol. 2019 Feb;20(2):282-296
pubmed: 30665869
Biochem J. 2011 Jul 15;437(2):199-213
pubmed: 21711248
Hepatol Res. 2019 Jan;49(1):111-117
pubmed: 30144256
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Clin Nutr ESPEN. 2018 Jun;25:145-148
pubmed: 29779810
Dig Dis. 2015 Oct;33(6):765-70
pubmed: 26488173
Oncotarget. 2016 Feb 9;7(6):7207-15
pubmed: 26769852
Int J Cancer. 2008 Feb 1;122(3):664-71
pubmed: 17943726
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
J Thyroid Res. 2014;2014:638747
pubmed: 25295214
Cancer Med. 2019 Jan;8(1):137-146
pubmed: 30575325
J Clin Oncol. 2015 Feb 20;33(6):550-8
pubmed: 25512453
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
Hepatol Res. 2018 Nov;48(12):956-966
pubmed: 29845710
J Gastroenterol. 2017 Apr;52(4):512-519
pubmed: 27704266
Clin Cancer Res. 2008 Sep 1;14(17):5459-65
pubmed: 18765537